OBJECTIVE: The aim of this study was to evaluate the effect and tolerability oflow doses of transdermal (TD) buprenorphine patches in opioid-naive patients withcancer pain. METHODS: This was a nonrandomized, open-label, uncontrolled study inconsecutive opioid-naive patients with advanced cancer and moderate pain. TDbuprenorphine was initiated at a dose of 17.5 microg/h (0.4 mg/d), with patchchanges every 3 days. Doses were then adjusted according to the clinicalresponse. Pain intensity, opioid-related adverse effects, TD buprenorphine doses,and quality of life were monitored over 4 weeks. The time to dose stabilizationand indexes of dose escalation were also calculated. RESULTS: Thirty-nineconsecutive patients completed all 4 weeks of the study. Low doses of TDbuprenorphine were well tolerated and effective in these opioid-naive patientswith cancer pain. Pain control was achieved within a mean of 1.5 days after thestart of TD buprenorphine therapy. The mean TD buprenorphine dose wassignificantly increased from baseline beginning at 2 weeks after the start oftherapy and had doubled by 4 weeks (P < 0.05). Pain intensity was significantlydecreased from baseline beginning at 1 week and continuing through the remaining weekly evaluations (P < 0.05). The mean buprenorphine escalation index,calculated as a percentage and in milligrams, was 41.2% and 0.2 mg, respectively.Quality of life improved significantly over the study period (P = 0.007). Therewere no significant changes in opioid-related symptoms between weeklyevaluations. CONCLUSION: Observations from this study suggest that randomized,controlled, double-blind studies of TD buprenorphine 17.5 microg/h inopioid-naive patients with cancer pain may be warranted.
|Numero di pagine||5|
|Stato di pubblicazione||Published - 2009|
All Science Journal Classification (ASJC) codes